Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3241 in Parkinson's disease with PET assessment of microglial activation
2011-004803-19Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing AZD3241 with Placebo (2 arms). Primary endpoint: Effect of AZD3241 on microglial activation. Started Dec 2011; status: completed.
02
Drugs
verdiperstat
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2011-004803-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004803-19.